Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096043 · ClinicalTrials.gov registry record · Phase 2
A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT01096043 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 69 participants.
The verdict
NCT01096043, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
Study CXL-1020-02 employs is designed to further define suitable clinical dosages for CXL-1020 which will be utilized in a later Phase IIb study. The study is conducted in 3 different stages called 'strata" and evaluates the potential utility of this drug for the treatment of patents who are hospitalized with heart failure.
Interventions
- DRUG Placebo
- DRUG Strata 1 CXL-1020
- DRUG Strata 2 CXL-1020
- DRUG Strata 3 CXL-1020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01096043
The ClinicalTrials.gov registry entry for NCT01096043 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01096043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01096043 about?
NCT01096043 is a clinical study titled "A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure". Study CXL-1020-02 employs is designed to further define suitable clinical dosages for CXL-1020 which will be utilized in a later Phase IIb study. The study is conducted in 3 different stages called 'strata" and evaluates the potential utility of this drug for the treatment of patents who are hospita...
What is the current status of trial NCT01096043?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2010-04. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01096043?
The interventions under investigation include: Placebo (DRUG), Strata 1 CXL-1020 (DRUG), Strata 2 CXL-1020 (DRUG), Strata 3 CXL-1020 (DRUG).
Who is sponsoring clinical trial NCT01096043?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.